Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

An Architecture for the Integration of Clinical Data from a PEHR in a Regional Research Platform.

Schreiweis B, Bronsch T, Stein KE, Nöst S, Aguduri LS, Brandner A, Pensold P, Weiss N, Yüksekogul N, Bergh B, Heinze O.

Stud Health Technol Inform. 2016;228:272-6.

PMID:
27577386
2.

Patient Portal Integration - A Native IHE Connector Implementation for PEHR.

Yüksekogul N, Schreiweis B, Weiss N, Aguduri LS, Brandner A, Bronsch T, Pensold P, Stein KE, Helmer A, Bergh B, Heinze O.

Stud Health Technol Inform. 2016;228:172-6.

PMID:
27577365
3.

Implementing PEHR: Design and Integration of a Consent Creator Service.

Weiss N, Aguduri LS, Yüksekogul N, Schreiweis B, Brandner A, Bronsch T, Pensold P, Stein KE, Bergh B, Heinze O.

Stud Health Technol Inform. 2016;228:167-71.

PMID:
27577364
4.

The Patient Portal of the Personal Cross-Enterprise Electronic Health Record (PEHR) in the Rhine-Neckar-Region.

Brandner A, Schreiweis B, Aguduri LS, Bronsch T, Kunz A, Pensold P, Stein KE, Weiss N, Yüksekogul N, Bergh B, Heinze O.

Stud Health Technol Inform. 2016;228:157-61.

PMID:
27577362
5.

Implementing the Patient Portal of the PEHR in the Metropolitan Region Rhine-Neckar - Experiences with Liferay.

Pensold P, Schneider G, Aguduri LS, Brandner A, Bronsch T, Schreiweis B, Stein KE, Weiss N, Yüksekogul N, Bergh B, Heinze O.

Stud Health Technol Inform. 2016;228:105-9.

PMID:
27577351
6.

Medication-Taking Practices of Patients on Antiretroviral HIV Therapy: Control, Power, and Intentionality.

Muessig KE, Panter AT, Mouw MS, Amola K, Stein KE, Murphy JS, Maiese EM, Wohl DA.

AIDS Patient Care STDS. 2015 Nov;29(11):606-16. doi: 10.1089/apc.2015.0058.

7.

Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial.

Hagopian W, Ferry RJ Jr, Sherry N, Carlin D, Bonvini E, Johnson S, Stein KE, Koenig S, Daifotis AG, Herold KC, Ludvigsson J; Protégé Trial Investigators.

Diabetes. 2013 Nov;62(11):3901-8. doi: 10.2337/db13-0236. Epub 2013 Jun 25.

8.

Nonclinical evaluation of GMA161--an antihuman CD16 (FcγRIII) monoclonal antibody for treatment of autoimmune disorders in CD16 transgenic mice.

Flaherty MM, MacLachlan TK, Troutt M, Magee T, Tuaillon N, Johnson S, Stein KE, Bonvini E, Garman R, Andrews L.

Toxicol Sci. 2012 Jan;125(1):299-309. doi: 10.1093/toxsci/kfr278. Epub 2011 Oct 24.

PMID:
22025730
9.

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.

Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr, Bode B, Aronoff S, Holland C, Carlin D, King KL, Wilder RL, Pillemer S, Bonvini E, Johnson S, Stein KE, Koenig S, Herold KC, Daifotis AG; Protégé Trial Investigators.

Lancet. 2011 Aug 6;378(9790):487-97. doi: 10.1016/S0140-6736(11)60931-8. Epub 2011 Jun 28.

10.

A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs.

Shankar G, Pendley C, Stein KE.

Nat Biotechnol. 2007 May;25(5):555-61. Review.

PMID:
17483842
11.

Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization.

Veri MC, Gorlatov S, Li H, Burke S, Johnson S, Stavenhagen J, Stein KE, Bonvini E, Koenig S.

Immunology. 2007 Jul;121(3):392-404. Epub 2007 Mar 26.

12.

Dens invaginatus of the mandibular first molars in a dog.

Stein KE, Marretta SM, Eurell JA.

J Vet Dent. 2005 Mar;22(1):21-5.

PMID:
15909453
13.

Comparison of hand-instrumented, heated gutta-percha and engine-driven, cold gutta-percha endodontic techniques.

Stein KE, Manfra Marretta S, Siegel A, Vitoux J.

J Vet Dent. 2004 Sep;21(3):136-45.

PMID:
15580822
14.
15.
16.

The Sr1 gene that controls diversity of the anti-inulin antibody response maps to mouse chromosome 14.

Jones Tiffany L, Riblet R, Stein KE.

Immunogenetics. 2003 May;55(2):80-6. Epub 2003 Apr 9.

PMID:
12684850
17.
18.

Immunogenicity: concepts/issues/concerns.

Stein KE.

Dev Biol (Basel). 2002;109:15-23.

PMID:
12434909
19.

Impact of cell culture process changes on endogenous retrovirus expression.

Brorson K, De Wit C, Hamilton E, Mustafa M, Swann PG, Kiss R, Taticek R, Polastri G, Stein KE, Xu Y.

Biotechnol Bioeng. 2002 Nov 5;80(3):257-67.

PMID:
12226857
20.

Evaluation of a quantitative product-enhanced reverse transcriptase assay to monitor retrovirus in mAb cell-culture.

Brorson K, Xu Y, Swann PG, Hamilton E, Mustafa M, de Wit C, Norling LA, Stein KE.

Biologicals. 2002 Mar;30(1):15-26.

PMID:
11846426
21.

The regulation of biologic products derived from bioengineered plants.

Stein KE, Webber KO.

Curr Opin Biotechnol. 2001 Jun;12(3):308-11. Review.

PMID:
11404111
22.

Use of a quantitative product-enhanced reverse transcriptase assay to monitor retrovirus levels in mAb cell-culture and downstream processing.

Brorson K, Swann PG, Lizzio E, Maudru T, Peden K, Stein KE.

Biotechnol Prog. 2001 Jan-Feb;17(1):188-96. Erratum in: Biotechnol Prog 2001 May-Jun;17(3):586.

PMID:
11170498
23.

The ability of B cells and dendritic cells to present antigen increases during ontogeny.

Muthukkumar S, Goldstein J, Stein KE.

J Immunol. 2000 Nov 1;165(9):4803-13.

24.

A novel activation induced lymphocyte surface antigen, 90.12, is also expressed on apoptotic cells.

Clark KJ, Monser M, Stein KE, Shapiro MA.

Scand J Immunol. 2000 Feb;51(2):155-63.

26.

Mutational analysis of avidity and fine specificity of anti-levan antibodies.

Brorson K, Thompson C, Wei G, Krasnokutsky M, Stein KE.

J Immunol. 1999 Dec 15;163(12):6694-701.

27.

Determination of the IgG2a allotype of CXB recombinant inbred mouse strains by a PCR-based method.

Tiffany LJ, Garcia-Ojeda PA, Stein KE.

Immunogenetics. 1999 Oct;50(1-2):71-3. No abstract available. Erratum in: Immunogenetics 2000 Mar;51(3):252.

PMID:
10541809
28.

Murine immune responses to Neisseria meningitidis group C capsular polysaccharide and a thymus-dependent toxoid conjugate vaccine.

Rubinstein LJ, García-Ojeda PA, Michon F, Jennings HJ, Stein KE.

Infect Immun. 1998 Nov;66(11):5450-6.

29.

xid affects events leading to B cell cycle entry.

Brorson K, Brunswick M, Ezhevsky S, Wei DG, Berg R, Scott D, Stein KE.

J Immunol. 1997 Jul 1;159(1):135-43.

PMID:
9200448
30.

Overcoming obstacles to monoclonal antibody product development and approval.

Stein KE.

Trends Biotechnol. 1997 Mar;15(3):88-90.

PMID:
9080714
32.

Immunoglobulin isotype switching in xid mice.

Brorson KA, Krasnokutsky MV, Stein KE.

Mol Immunol. 1995 May;32(7):487-94.

PMID:
7783751
33.

Glycoconjugate vaccines. What next?

Stein KE.

Int J Technol Assess Health Care. 1994 Winter;10(1):167-76. Review.

PMID:
8157449
34.

The absorption and bioactivity of bacterially synthesized menaquinones.

Conly JM, Stein KE.

Clin Invest Med. 1993 Feb;16(1):45-57.

PMID:
8467580
35.

Strain-dependent restricted VH and VL usage by anti-bacterial levan monoclonal antibodies.

Boswell CM, Irwin DC, Goodnight J, Stein KE.

J Immunol. 1992 Jun 15;148(12):3864-72.

PMID:
1602134
36.

Thymus-independent and thymus-dependent responses to polysaccharide antigens.

Stein KE.

J Infect Dis. 1992 Jun;165 Suppl 1:S49-52. Review.

PMID:
1588177
37.

VH gene family expression in mice with the xid defect.

Feng SH, Stein KE.

J Exp Med. 1991 Jul 1;174(1):45-51.

38.

A simple method for coating native polysaccharides onto nitrocellulose.

Feng SH, Rubinstein LJ, Stein KE.

J Immunol Methods. 1991 Mar 21;137(2):261-6.

PMID:
1707430
39.

Production and characterization of monoclonal anti-CD18 anti-idiotype antibodies.

Stein KE, Epstein S.

Mol Immunol. 1991 Jan-Feb;28(1-2):193. No abstract available.

PMID:
1672729
40.

Capsular polysaccharide of Haemophilus influenzae type b (Hib PS) is a mitogen for murine B cells.

Shin HS, Stein KE.

J Immunol. 1990 Oct 15;145(8):2772-3. No abstract available.

PMID:
2212662
41.
42.

Murine immune response to the Neisseria meningitidis group C capsular polysaccharide. I. Ontogeny.

Rubinstein LJ, Stein KE.

J Immunol. 1988 Dec 15;141(12):4352-6.

PMID:
3143762
43.

An avidin-biotin based ELISA for quantitation of antibody to bacterial polysaccharides.

Sutton A, Vann WF, Karpas AB, Stein KE, Schneerson R.

J Immunol Methods. 1985 Oct 10;82(2):215-24.

PMID:
3900215
44.

Network regulation of the immune response to bacterial polysaccharide antigens.

Stein KE.

Curr Top Microbiol Immunol. 1985;119:57-74. Review. No abstract available.

PMID:
3910365
48.

Immune response to a thymus-dependent form of B512 dextran requires the presence of Lyb-5+ lymphocytes.

Stein KE, Zopf DA, Miller CB, Johnson BM, Mongini PK, Ahmed A, Paul WE.

J Exp Med. 1983 Feb 1;157(2):657-66.

49.

Comparison of RIA and IRMA methods for measurement of carcinoembryonic antigen (CEA).

Valdes R Jr, Stein KE.

Clin Biochem. 1982 Oct;15(5):241-7.

PMID:
7151270
50.

The immune response to an isomaltohexosyl-protein conjugate, a thymus-dependent analogue of alpha(1 replaced by 6) dextran.

Stein KE, Zopf DA, Johnson BM, Miller CB, Paul WE.

J Immunol. 1982 Mar;128(3):1350-4.

PMID:
6173433

Supplemental Content

Loading ...
Support Center